News & Updates

Bimekizumab outperformed risankizumab in the American College of Rheumatology ≥50 percent response criteria (ACR50) among patients with active psoriatic arthritis (PsA) in the phase IIIb BE BOLD trial – the first head-to-head PsA study to demonstrate superiority for a joint-focused primary endpoint. 

Prenatal paracetamol exposure is not associated with an increased risk of attention‑deficit/ hyperactivity disorder (ADHD) or autism spectrum disorder (ASD), according to researchers from the University of Hong Kong (HKU).

Hypofractionated proton therapy achieves an 8-month survival rate of 100 percent, preserves quality of life (QoL), and also lowers radiation exposure to the lungs and heart and reduces toxicity (eg, skin-related reactions) in Chinese patients with breast cancer compared with traditional photon radiotherapy, according to two first-of-its-kind studies in Asia conducted by researchers at the Hong Kong Sanatorium & Hospital (HKSH).

Surrogate indexes calculated from oral glucose tolerance tests (OGTTs) effectively predict the development of type 2 diabetes (T2D), suggests a US study. On the other hand, measures based on fasting insulin are more useful than those that do not measure insulin.